Key result
Renin-angiotensin system blockade is effective in preventing new-onset or recurrent atrial fibrillation in patients with hypertension, heart failure, or undergoing electrical cardioversion.
Why the study?
Does renin-angiotensin system blockade prevent new-onset or recurrent atrial fibrillation in at-risk patient populations?
Does renin-angiotensin system blockade prevent new-onset or recurrent atrial fibrillation in at-risk patient populations?
This review highlights the potential of renin-angiotensin system blockade as a therapeutic strategy to prevent new-onset or recurrent atrial fibrillation in susceptible populations.
May support RAS blockade to prevent AF in hypertension with LVH; leaves open need for dedicated RCTs to guide practice.
There is growing evidence to suggest a role for the renin-angiotensin system (RAS) in the pathogenesis of atrial fibrillation (AF). Experimental animal data suggest RAS-dependent mechanisms for the development of a structural and electrophysiologic substrate for AF. This is consistent with clinical data demonstrating the effectiveness of RAS blockade in preventing new-onset or recurrent AF in a variety of patient populations including patients with hypertension and left ventricular hypertrophy, congestive heart failure, and those undergoing electrical cardioversion for AF. This review summarizes experimental and clinical evidence to date relating to the role of RAS in the pathogenesis of AF, and the efficacy of its inhibition in managing this common arrhythmia.
No takes yet. Share an insight, caveat, or question.
Patlolla et al. (2006) conducted a review in Atrial fibrillation. Renin-angiotensin system (RAS) blockade was evaluated. Renin-angiotensin system blockade is effective in preventing new-onset or recurrent atrial fibrillation in patients with hypertension, heart failure, or undergoing electrical cardioversion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: